GLP-2
Glucagon-Like Peptide-2
A 33-amino acid peptide secreted by intestinal L-cells that promotes intestinal growth, enhances nutrient absorption, and repairs gut mucosal integrity. The synthetic analog teduglutide (Gattex) is FDA-approved for short bowel syndrome.
Mechanism of Action
GLP-2 binds GLP-2 receptors on intestinal subepithelial myofibroblasts, stimulating IGF-1 and EGF release that drives enterocyte proliferation and reduces apoptosis. It increases villus height, crypt depth, and mucosal surface area while reducing intestinal permeability and inflammation.
Health Claims & Evidence
Promotes intestinal mucosal growth and repair
Reduces intestinal permeability (leaky gut)
Enhances nutrient absorption in intestinal failure
Short-Term Effects
Improved intestinal absorption and reduced diarrhea within 1–2 weeks.
Long-Term Effects
Sustained intestinal mucosal growth and reduced parenteral nutrition dependence.
Side Effects
Abdominal pain, nausea, injection site reactions. Monitor for intestinal polyps with long-term use.
Contraindications
Active GI malignancy or history of GI cancer. Monitor for colorectal polyps.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
GLP-2 and intestinal adaptation
Drucker et al. · Proceedings of the National Academy of Sciences · 1996
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on GLP-2 and related peptides, and prepare an educational research summary.
Explore Research